Postmenopausal Osteoporosis Market - Top Companies and Manufacturers

In the News

• Innovent Biologics, Inc. and Indonesian biotechnology company PT Etana Biotechnologies Indonesia jointly announced that Bevagen (bevacizumab biosimilar), a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody drug, was approved for five indications: metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple-negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC), primary peritoneal cancer (OC), and cervical cancer (CC).
• Pfizer Inc. returned, in improved packaging, the menopause hormone therapy DUAVEE to the U.S. market. This return follows a voluntary recall due to a packaging problem that had nothing to do with worries about the product's efficacy or safety. It is anticipated that this relaunch plan will fix the packaging problems and increase sales revenue.